AEMD READ THE FULL AEMD RESEARCH REPORT Assessing if the Hemopurifier in conjunction with standard of care treatment can increase the population that can benefit from combined treatment Aethlon ...

A new study by investigators from Europe, including the Netherlands and the United Kingdom (UK), has shed light on ...

Natural products industry companies share overviews on the latest science on their dietary supplement branded ingredients and ...

I-Mab (NASDAQ: IMAB) (the Company), a U.S.-based, global biotech company, focused on the development of precision immuno-oncology agents for the treatment of cancer, today announced publication of the ...

Cassava Sciences (SAVA) announced that the Company presented a poster at the TSC International Research Conference held June 26-28, 2025 in ...

The ADA Scientific Sessions is a globally recognized conference dedicated to advancing the field of diabetes. This annual meeting serves as a critical forum for presenting cutting-edge research, ...

On April 26, 2025, Dr. Sarah Ronis, a Clinical & Translational Science (CTS) Research Program awardee and recent Co-Investigator on a 2024 Annual Pilot award with the Clinical and Translational ...

BI-1910 Poster at PAGE 2025 Title: A population modelling framework to support early clinical development of BI-1910, an agonist monoclonal antibody for tumor necrosis factor 2 Abstract Number : 11618 ...

Poster Title: Results of a Phase 2a Clinical Trial of Inhaled Mebufotenin (GH001) in Patients with Postpartum Depression Presenting Author: Claus Bo Svendsen, GH Research, Dublin, Ireland ...

LONDON, April 28, 2025 (GLOBE NEWSWIRE) -- Spur Therapeutics today announced that it will share new data from its gene therapy programs in Gaucher disease, GBA1 Parkinson's disease and ...

Radiant Biotherapeutics Announces Poster Presentation at 2025 American Association for Cancer Research (AACR) Annual Meeting Media: Jeffrey Krasner Slowey McManus Communications jkrasner ...

The second poster will include background and study design for the ongoing HEROEX-1 Phase 1a/1b clinical trial (NCT06521554) evaluating the overall safety and tolerability of NVL-330 for pre ...